Equities

Nightingale Health Oyj

Nightingale Health Oyj

Actions
Health CareMedical Equipment and Services
  • Price (EUR)1.58
  • Today's Change-0.025 / -1.56%
  • Shares traded34.92k
  • 1 Year change+57.19%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nightingale Health Oyj is a Finland-based health technology company that aims to promote preventative health and help people stay healthy. The blood analysis technology developed by Nightingale measures a broad group of biomarkers from a single blood sample, recognizing individual disease risks. The Company provides people with comprehensive insights on health, helps them make better decisions regarding their health and connects them with healthcare experts that offer preventative services for maintaining health. Nightingale Health Oy is the Parent Company in the Nightingale Group. The Group comprises the parent Company’s subsidiaries: Nightingale Health United States Inc, Nightingale Health Asia Pte Ltd, Nightingale Health Japan KK as well as NG Health Sweden AB. The Company owns and independently oversees two laboratories in Finland, in Helsinki and Kuopio, and one laboratory in Tokyo, Japan.

  • Revenue in EUR (TTM)3.65m
  • Net income in EUR-18.06m
  • Incorporated2002
  • Employees81.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
HEALTH:HEX since
announced
Transaction
value
Welltus IncAnnounced07 Mar 202407 Mar 2024Announced47.20%--
Data delayed at least 15 minutes, as of May 16 2024.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Initiator Pharma A/S0.00-3.06m40.89m2.00--27.12-----0.6567-0.65670.000.33190.00----0.00-58.55-65.10-62.50-70.59------------0.5804------40.52------
Promimic AB3.18m-791.72k41.65m17.00--6.32--13.09-0.5283-0.52832.084.110.3994-5.633.002,180,588.00-9.93-24.89-11.67-29.25103.90101.23-24.88-89.473.98--0.00--128.63--41.95------
Bergenbio ASA30.49k-16.40m43.96m18.00--2.75--1,442.03-0.2647-0.26470.00020.04740.0021-------111.66-66.15-176.09-78.74-----53,785.59-11,419.44----0.00---9.00-31.4336.98------
Enzymatica AB (publ)4.06m-4.61m47.19m18.00--6.55--11.62-0.3247-0.32470.28660.48410.32691.386.48---37.11-27.36-39.16-33.9864.2565.08-113.50-66.12---23.260.2502--4.00-0.638227.57--7.02--
Hamlet BioPharma AB0.00-2.28m49.25m7.00--12.67-----0.207-0.2070.000.35430.00-------63.29-83.52-69.05-107.84------------0.0984-------18.87--78.01--
Oncopeptides AB3.02m-21.39m50.36m57.00--6.21--16.66-1.96-1.960.27760.44740.1129--1.44617,894.80-79.88-141.28-101.04-200.49103.06---707.30-2,689.06----0.7065--321.54--26.29------
Gentian Diagnostics ASA12.25m-502.35k50.47m58.00--3.87163.704.12-0.3783-0.37839.229.820.76461.856.352,452,035.00-3.14-10.76-3.58-11.8650.8441.46-4.10-26.994.14--0.0555--32.9827.6354.92---4.92--
Cantargia AB0.00-24.04m56.77m22.00--3.92-----1.65-1.650.000.91860.00----0.00-80.18-55.08-100.27-61.35------------0.00------24.69------
Alligator Bioscience AB4.76m-21.36m57.85m55.00------12.14-0.4848-0.48480.0999-0.07720.5289--8.07956,741.40-237.13-73.26---91.33-----448.35-811.68---104.20----62.7816.60-28.53---20.34--
Moberg Pharma AB (publ)70.40k-1.94m60.24m9.00--1.14--855.69-1.09-1.090.037921.630.0014--0.2841---3.81---3.96--60.00---2,751.22--1.73--0.0073---100.00---34.26------
Nightingale Health Oyj3.65m-18.06m61.79m81.00--1.05--16.91-0.2979-0.29790.06031.500.03441.603.8744,560.98-17.02-14.20-18.12-15.6975.8183.57-494.25-408.5014.15--0.0378--80.8019.05-12.38------
Intellego Technologies AB16.01m5.12m61.88m62.0011.744.7711.423.862.332.337.355.740.88413.873.693,007,968.0028.26--44.00--68.73--31.96--2.075.820.1684--222.74--493.56------
Orexo AB53.15m-6.30m63.03m113.00--11.87126.571.19-2.13-2.1317.981.780.69591.082.535,337,069.00-8.25-6.41-20.27-9.9988.1486.76-11.86-11.830.5890.13860.8948--2.32-3.9927.76--25.77--
IRLAB Therapeutics AB487.46k-13.50m67.80m28.00--10.31--139.09-3.03-3.030.10951.480.0274--0.4652218,384.60-75.97-27.12-94.23-30.42-1,952.47-72.18-2,770.38-155.57----0.2646---90.71216.07-56.82---22.56--
Vistin Pharma ASA37.75m4.84m84.02m77.0017.353.2813.172.231.271.279.886.701.112.317.445,692,663.0014.281.7318.932.1159.9358.9212.832.360.853632.960.0934--51.3516.951,066.84---0.1922--
Data as of May 16 2024. Currency figures normalised to Nightingale Health Oyj's reporting currency: Euro EUR

Institutional shareholders

11.15%Per cent of shares held by top holders
HolderShares% Held
Nordea Investment Management AB (Finland)as of 29 Feb 20241.90m4.83%
Fj�rde AP-fondenas of 31 Dec 20231.06m2.70%
Norges Bank Investment Managementas of 31 Dec 2023793.40k2.02%
Sp-Fund Management Co. Ltd.as of 30 Apr 2024475.74k1.21%
Kieger AGas of 31 Mar 2023150.00k0.38%
S-Bank Fund Management Ltd.as of 31 Dec 20230.000.00%
DNCA Finance SAas of 30 Jun 20230.000.00%
More ▼
Data from 31 Mar 2023 - 15 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.